|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999-2017显示文摘Objective: Breast cancer in young females was usually considered more aggressive and requires aggressive therapy. We investigated whether early detection and improved treatments changed the patterns of characteristics,management and outcomes of young breast cancer patients over time.Methods: Females under 40 years of age diagnosed with breast cancer during the periods 1999-2017 and1999-2015 were identified in the Fudan University Shanghai Cancer Center(FUSCC) and the population-based Surveillance, Epidemiology, and End Results(SEER) registry, respectively. Clinicopathologic characteristics and treatment information were collected. Patients diagnosed before 2013 were followed up.Results: The proportions of young breast cancer patients were 15.0% and 5.3% in the FUSCC and SEER cohorts, respectively. In the FUSCC cohort, there was a significant increase in the proportion of ductal carcinoma in situ(DCIS)(from 8.8% to 16.9%;P<0.0001) and it remained stable in SEER cohort. The proportion of T1-stage tumors increased dramatically in the FUSCC cohort(from 35.3% to 41.9%;P=0.008), whereas it decreased in SEER cohort(from 42.4% to 33.0%;P<0.0001). The percentage of estrogen receptor(ER)-positive cancers was consistently increased in both the invasive ductal carcinoma(IDC) and DCIS patients in the two cohorts. Breastconserving surgery and immediate implant reconstruction after mastectomy both exhibited increased use over time in the FUSCC cohort. Both the FUSCC and SEER cohorts showed a significantly better prognosis in the recent time period.Conclusions: With the increased early-stage and ER-positive diseases in young patients as well as better systemic treatment strategies, improved survival has been observed in recent years. There has been a substantial deescalation in surgical therapies in young breast cancer patients. | Rong Guo Jing Si Jingyan Xue Yonghui Su Miao Mo Benlong Yang Qi Zhang Weiru Chi Yayun Chi Jiong Wu | 2019 | Chinese Journal of Cancer Research2019，31，4： | 24 |
| 2 | Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy显示文摘Objective: Patients preoperatively diagnosed with ductal carcinoma in situ(DCIS) by core needle biopsy(CNB) exhibit a significant risk for upstaging on final pathology, which leads to major concerns of whether axillary staging is required at the primary operation. The present study aimed to identify clinicopathological factors associated with upstaging in patients preoperatively diagnosed with DCIS by CNB.Methods: The present study enrolled 604 patients(cN0 M0) with a preoperative diagnosis of pure DCIS by CNB, who underwent axillary staging between August 2006 and December 2015, at Fudan University Shanghai Cancer Center(Shanghai, China).Predictive factors of upstaging were analyzed retrospectively.Results: Of the 604 patients, 20.03%(n = 121) and 31.95%(n = 193) were upstaged to DCIS with microinvasion(DCISM) and invasive breast cancer(IBC) on final pathology, respectively. Larger tumor size on ultrasonography(> 2 cm) was independently associated with upstaging [odds ratio(OR) 1.558, P = 0.014]. Additionally, patients in lower breast imaging reporting and data system(BI-RADS) categories were less likely to be upstaged(4 B vs. 5: OR 0.435, P = 0.002;4 C vs. 5: OR 0.502, P = 0.001). Overall,axillary metastasis occurred in 6.79%(n = 41) of patients. Among patients with axillary metastasis, 1.38%(4/290), 3.31%(4/121)and 17.10%(33/193) were in the DCIS, DCISM, and IBC groups, respectively.Conclusions: For patients initially diagnosed with DCIS by CNB, larger tumor size on ultrasonography(> 2 cm) and higher BIRADS category were independent predictive factors of upstaging on final pathology. Thus, axillary staging in patients with smaller tumor sizes and lower BI-RADS category may be omitted, with little downstream risk for upstaging. | Jing Si Benlong Yang Rong Guo Naisi Huang Chenlian Quan Linxiaoxi Ma Bingqiu Xiu Yun Cao Yue Tang Linxiao Shen Jiajian Chen Jiong Wu | 2019 | Cancer Biology & Medicine2019，16，2： | 3 |
| 3 | Catalytic chemodivergent annulations betweenα-diketones and alkynylα-diketones显示文摘Four types of unprecedented and chemodivergent reactions betweenα-diketones and alkynylα-diketones have been achieved under the catalysis of phosphine and Br?nsted base,respectively,leading to the rapid construction of four different classes of biologically important but synthetically challenging molecular scaffolds including 2-hydroxyfuran-3(2H)-ones,4-hydroxy-2-oxabicyclo[2.2.1]heptan-3-ones,1,3-diaryl cyclobutanes,and 4-(furan-2(3H)-ylidene)cyclopent-2-enones.The formation of the products includes two novel rearrangement processes,and further transformations on the products can be easily achieved to deliver value-added substances such as highly functionalized cyclopentanes.Moreover,the 2-hydroxyfuran-3(2H)-one products display promising photophysical properties such as green luminescence under UV light and aggregation-induced emission effect,showing the practical application value of this work.The great potential ofα-diketones in both synthetic chemistry and material science has been unambiguously demonstrated. | Xiangwen Kong Fang Yu Zhizhou Chen Fan Gong Shuang Yang Jinggong Liu Benlong Luo Xinqiang Fang | 2021 | Science China Chemistry2021，64，6： | 0 |
| 4 | Copper-catalyzed diversified annulations betweenα-diketones and alkynylα-diketones显示文摘Copper-catalyzed divergent annulations betweenα-diketones and alkynylα-diketones have been achieved,delivering a series of highly functionalized and biologically important cis-hexahydro-2Hcyclopenta[b]furan(HCPF)and 2-hydroxydihydrofuran-3(2H)-one(HDFO)products with high levels of stereoselectivity under identical conditions.The protocol features the use of earth-abundant copper catalyst,mild conditions,shortening synthetic routes in constructing different molecular frameworks,and reducing the corresponding possible waste production.The substituents of the nucleophilicα-diketones play crucial roles in switching the reaction pathways. | Xiangwen Kong Fang Yu Shengtong Niu Fan Gong Shuang Yang Jinggong Liu Benlong Luo Xinqiang Fang | 2022 | Chinese Chemical Letters2022，33，6： | 0 |
| 5 | CACA Guidelines for Holistic Integrative Management of Breast Cancer显示文摘Purpose:Breast cancer is now the most common malignant tumor worldwide.About one-fourth of female cancer patients all over the world sufer from breast cancer.And about one in six female cancer deaths worldwide is caused by breast cancer.In terms of absolute numbers of cases and deaths,China ranks frst in the world.The CACA Guidelines for Holistic Integrative Management of Breast Cancer were edited to help improve the diagnosis and comprehensive treatment in China.Methods:The Grading of Recommendations Assessment,Development and Evaluation(GRADE)was used to classify evidence and consensus.Results:The CACA Guidelines for Holistic Integrative Management of Breast Cancer include the epidemiology of breast cancer,breast cancer screening,breast cancer diagnosis,early breast cancer treatment,advanced breast cancer treatment,follow-up,rehabilitation,and traditional Chinese medicine treatment of breast cancer patients.Conclusion:We to standardize the diagnosis and treatment of breast cancer in China through the formulation of the CACA Guidelines. | Jiong Wu Daiming Fan Zhimin Shao Binghe Xu Guosheng Ren Zefei Jiang Yongsheng Wang Feng Jin Jin Zhang Qingyuan Zhang Fei Ma Jinli Ma Zhonghua Wang Shusen Wang Xiaojia Wang Shu Wang Haibo Wang Tao Wang Xiang Wang Jing Wang Jia Wang Biyun Wang Li Fu Hongyuan Li Yehui Shi Lu Gan Yunjiang Liu Jian Liu Zhenzhen Liu Qiang Liu Qiang Sun Wenwu Cheng Keda Yu Zhongsheng Tong Xinhong Wu Chuangui Song Jianguo Zhang Jian Zhang Junjie Li Bin Li Man Li Huiping Li Wentao Yang Hongjian Yang Benlong Yang Hong Bu Juping Shen Zhenzhou Shen Yiding Chen Ceshi Chen Da Pang Zhimin Fan Ying Zheng Xiaoli Yu Guangyu Liu Xichun Hu Yiqun Ling Jinhai Tang Yongmei Yin Cuizhi Geng Peng Yuan Yajia Gu Cai Chang Xuchen Cao Yuan Sheng Yuanxi Huang Jian Huang Weijun Peng Xiaohua Zeng Yuntao Xie Ning Liao Committee of Breast Cancer Society,Chinese Anti-Cancer Association | 2022 | Holistic Integrative Oncology2022，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员